ECG Screening for the iPhone®

AliveCor’s Heart Monitor for the iPhone® is now available for purchase to U.S. medical professionals. The FDA-cleared mobile device-based ECG monitor allows medical professionals to quickly and accurately measure and detect cardiac arrhythmias including atrial fibrillation. The Heart Monitor, which is cleared for use with the iPhone® 4 or 4S, is available for purchase by licensed U.S. medical professionals for $199, and will be available for sale in Europe this spring.

In February 2011, EP Lab Digest® spoke with Dr. David Albert, Founder & Chief Medical Officer at AliveCor, about the AliveCor iPhone® ECG app. Check out the interview here.

For more electrophysiology news, please check out EP Lab Digest®’s daily news section!

Advertisements

Boston AF Symposium – 2013

This Thursday marks the start of the 18th Annual Boston Atrial Fibrillation Symposium, taking place January 17-19, 2013 at the Seaport Hotel and World Trade Center Boston. This is EP Lab Digest®’s 12th visit to this major scientific forum since our publication launch in September 2001. We look forward to seeing colleagues in the field as well as learning about the latest advances and strategies in the management of atrial fibrillation.

 

In a special blog this month, contributor Dr. Rishi Anand speaks with Dr. Moussa Mansour, one of the Course Directors of the 2013 Boston Atrial Fibrillation Symposium, about what to expect at this year’s meeting. Dr. Mansour notes there are several highlighted sessions this year, including featured sessions on new stroke prevention techniques, new catheter ablation techniques and mapping tools for atrial fibrillation, and information on clinical trials and regulatory issues.

 

We hope you will come by EP Lab Digest®’s booth (#902) at the meeting and say hello! In addition, for the latest updates and news from the Boston AF Symposium, please visit http://www.eplabdigest.com!

Top Stories of 2012

In the past year, EP Lab Digest® covered a wide array of popular topics in the EP field, including information on the S-ICD, rivaroxaban, FIRM ablation, social media, renal denervation, therapeutic hypothermia, and more. Below are some of the hot topics and top stories published in 2012:

Cryoballoon Ablation at the Mayo Clinic

• The Riata Recall

MR Conditional ICD Technology: Update

• A Comparison of the New Anticoagulants for Use in AF

• Ablating Rotors and Focal Beat Sources of Atrial Fibrillation to Improve Outcome: The CONFIRM Trial

CMS, DOJ, HRS, and ICDs: An Urgent Need for Clarity

Europe’s Leading Congresses in Cardiac Electrophysiology Agree to Consolidate Their Events and Develop a Common Scientific Program Each Year

• What to Do With the Left Atrial Appendage?

• Left Atrial Appendage Exclusion Using a LARIAT Device: A Case Study

Hybrid Ablation for Persistent Atrial Fibrillation: Initial Experience in a Community Hospital

• Intravascular Temperature Management Techniques in Therapeutic Hypothermia

Renal Denervation and Atrial Fibrillation: Interview with Dr. Jonathan Steinberg

• Boston Scientific Receives FDA Approval of First-in-Class S-ICD® System for Patients at Risk of Sudden Cardiac Arrest; S-ICD System is the World’s First and Only Commercially Available Completely Subcutaneous Implantable Defibrillator

• AliveCor’s Heart Monitor for iPhone Receives FDA Clearance

Social Media, mHealth and Medicine: 2012 in Review and Hopes for the Future

 

Update on FIRM Ablation

In the January 2013 issue of EP Lab Digest®, David E. Krummen, MD et al from the University of California and Veterans’ Affairs Healthcare System in San Diego, California, contribute an article on focal impulse and rotor modulation (FIRM) for the treatment of paroxysmal and persistent atrial fibrillation (AF). In the article, the authors summarize the evidence for stable electrical rotors and focal sources, but not CFAE sites, as sources of paroxysmal AF (and persistent AF), and their role as targets for ablation to achieve long-term maintenance of sinus rhythm. They write that there are ongoing studies to examine the efficacy of FIRM in providing high clinical efficacy while minimizing atrial ablation in patients with paroxysmal AF.

 

Sanjiv M. Narayan, MB, MD, PhD and colleagues first reported on focal impulse and rotor modulation in our March 2012 issue of EP Lab Digest®. The success of focal impulse and rotor modulation ablation for AF in their patient led to the CONFIRM trial, and to the initiation of clinical programs for FIRM ablation.

ELIQUIS® (apixaban) Approvals

There was big news today regarding ELIQUIS® (apixaban). Bristol-Myers Squibb Company and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved ELIQUIS® (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. ELIQUIS is expected to be widely available in the U.S. by the end of January 2013.

 

It was also announced in late December that the Japanese Ministry of Health, Labor and Welfare (MHLW) approved ELIQUIS® (apixaban) for the prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

 

For more information on available anticoagulants for use in atrial fibrillation, check out this article from the February 2012 issue of EP Lab Digest®.